

# Micromedex<sup>®</sup> policy on compendia drug content

## Data Sheet

Micromedex Solutions includes DRUGDEX<sup>®</sup> which is one of the statutorily named drug information compendia in the Medicaid program, for use in the determination of medically-accepted indications of drugs and biologicals used beyond package labeling in an anticancer chemotherapeutic regimen.

Micromedex contains FDA-approved indications as well as Non-FDA approved or off-label uses, based on peer reviewed, publicly available clinical or literature evidence. Discovery and adoption of new uses for marketed drugs often precedes FDA approval of such uses. US Food and Drug Administration (FDA) recognizes that these uses, or treatment regimens may be important therapeutic options and may even constitute a medically recognized standard of care, as are available in qualified Centers for Medicare and Medicaid Services (CMS) Compendia. Micromedex understands the importance of including such information in a truthful, non-misleading, and accurate manner for the consideration of health care professional individuals seeking information about a medical product.

To continue the long-standing reputation of Micromedex as a leading provider of unbiased information and to support robust and current information in drug therapy, Micromedex adheres to its policy for inclusion of non-biased, non-promotional, scientific or medical information on these drug uses in its databases and products.

## Identification of non-FDA approved uses

At Micromedex, there are two mechanisms for identifying these uses. First and foremost, such uses may be identified through routine monitoring of the primary literature. Second, uses may be identified through the consideration of external requests for inclusion in Micromedex databases and products.

Patient safety issues, breakthrough therapies, major treatment guideline updates, or other urgent situations are considered in prioritization of reviews. Public Health Agencies, such as CMS and FDA recognize that it may be in the best interest of public health for a firm to respond to unsolicited requests for information about Non-FDA approved uses.

## Research of non-FDA approved uses

Regardless of how the use is identified, members of the Micromedex editorial staff conduct a thorough search of the primary literature and other accepted sources of information to identify additional relevant evidence, including negative or inconclusive findings. This ensures all pertinent articles are considered in the analysis.

## Transparency

The Centers for Medicare and Medicaid Services (CMS) require compendia to provide transparency of processes used to evaluate therapies and to identify potential conflicts of interest. To meet these requirements, documents detailing transparency information for each drug/non-FDA approved use pair are posted at the Micromedex Compendia Resources website. Information is organized by drug name, with the document title indicating the use.

<https://www.merative.com/micromedex-training-center/compendia>

## Independent review

Uses are vetted by independent reviewers with expertise in a variety of specialties. Micromedex maintains independent off-label reviewers to facilitate the off-label process. Reviewers are health care professionals with board-certification or expertise in applicable specialty areas.

Reviewers must comply with the Micromedex Conflict of Interest Policy. Ratings are applied according to the editorial policy using a consensus methodology.

## Clinical review

Once identified, the evidence is critically evaluated for clinical relevance and statistical validity. If the body of evidence is deemed sufficient to warrant inclusion, the medical content about the drug is added to the Micromedex database. All new uses and revised existing uses with significant changes to the ratings require independent review.

## About Merative

Merative provides data and software for healthcare and government social services. With focused innovation and deep expertise, Merative works with providers, employers, health plans, governments, and life science companies to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022. Learn more at [merative.com](https://merative.com).

© Copyright Merative US L.P. 2023  
Merative  
100 Phoenix Drive  
Ann Arbor, Michigan 48108

Produced in the United States of America  
December 2023

Merative, the Merative logo, Micromedex, and DRUGDEX are trademarks of Merative in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies.

This document is current as of the initial date of publication and may be changed by Merative at any time. Not all offerings are available in every country in which Merative operates.

The information in this document is provided "as is" without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it. Merative does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation. The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user's responsibility to evaluate and verify the operation of any other products or programs with Merative product and programs.

Statement of Good Security Practices: IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. Merative systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. Merative does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.